Literature DB >> 11972097

Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP).

Beatrice Files1, Don Brambilla, Abdullah Kutlar, Scott Miller, Elliott Vichinsky, Winfred Wang, Suzanne Granger, Robert J Adams.   

Abstract

PURPOSE: Chronic red cell transfusion has been used for prevention of recurrent stroke in patients with sickle cell disease for three decades, and its effectiveness in primary prevention was recently shown. Iron overload, the inevitable result of chronic transfusion, is commonly monitored with serum ferritin concentration. PATIENTS AND METHODS: Sixty-one patients at high risk for stroke received chronic transfusion in a clinical trial of stroke prevention. A serum ferritin level of less than 500 ng/mL was required for study entry. Ferritin levels were obtained quarterly. Fifty patients who had four or more ferritin measurements were included in this analysis. Transfusions were administered as exchange or simple, with washed, reconstituted, or packed red blood cells, at the discretion of the site investigator.
RESULTS: Serum ferritin levels increased linearly with cumulative transfusion volume during the first four ferritin measurements, but the rate of increase varied widely among patients. Rates of increase varied similarly among 23 patients who received exclusively simple transfusion with packed red cells and in five patients who received exchange transfusions. Thirty-two patients received a total transfusion volume of more than 250 mL/kg. Ferritin continued to increase linearly after the first four measurements in 14, but the remaining 18 experienced a plateau before the level reached 3,000 ng/mL. Six of those with a linear increase never reached a ferritin level of 3,000 ng/dL.
CONCLUSIONS: There was strong intrapatient correlation between serum ferritin levels and volume transfused but wide interpatient variability early during chronic transfusion therapy. Intrapatient correlation declined at transfusion volumes of more than 250 mL/kg. Direct iron store assessment is needed to determine the clinical significance of serum ferritin variability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972097     DOI: 10.1097/00043426-200205000-00013

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  14 in total

1.  Erythrocytapheresis: Do Not Forget a Useful Therapy!

Authors:  Heidrun Ullrich; Roland Fischer; Regine Grosse; Uwe Kordes; Claudia Schubert; Bettina Altstadt; Georges Andreu
Journal:  Transfus Med Hemother       Date:  2008-01-15       Impact factor: 3.747

2.  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Authors:  Elizabeth S Klings; Roberto F Machado; Robyn J Barst; Claudia R Morris; Kamal K Mubarak; Victor R Gordeuk; Gregory J Kato; Kenneth I Ataga; J Simon Gibbs; Oswaldo Castro; Erika B Rosenzweig; Namita Sood; Lewis Hsu; Kevin C Wilson; Marilyn J Telen; Laura M Decastro; Lakshmanan Krishnamurti; Martin H Steinberg; David B Badesch; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

Review 3.  Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Winfred C Wang
Journal:  Cochrane Database Syst Rev       Date:  2017-01-17

4.  Iron overload during follow-up after tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma.

Authors:  Soo Jin Bae; Christine Kang; Ki Woong Sung; Hee Won Chueh; Meong Hi Son; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153

Review 5.  Screening children for sickle cell vasculopathy: guidelines for transcranial Doppler evaluation.

Authors:  Dorothy Bulas
Journal:  Pediatr Radiol       Date:  2005-02-10

6.  Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload.

Authors:  Sandhya R Panch; Yu Ying Yau; Kamille West; Karen Diggs; Tamsen Sweigart; Susan F Leitman
Journal:  Transfusion       Date:  2014-09-11       Impact factor: 3.157

7.  Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.

Authors:  Thomas V Adamkiewicz; Miguel R Abboud; Carole Paley; Nancy Olivieri; Melanie Kirby-Allen; Elliott Vichinsky; James F Casella; Ofelia A Alvarez; Julio C Barredo; Margaret T Lee; Rathi V Iyer; Abdullah Kutlar; Kathleen M McKie; Virgil McKie; Nadine Odo; Beatrice Gee; Janet L Kwiatkowski; Gerald M Woods; Thomas Coates; Winfred Wang; Robert J Adams
Journal:  Blood       Date:  2009-08-31       Impact factor: 22.113

8.  Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.

Authors:  Janet L Kwiatkowski
Journal:  J Blood Med       Date:  2011-09-21

Review 9.  Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Authors:  Winfred C Wang; Kerry Dwan
Journal:  Cochrane Database Syst Rev       Date:  2013-11-14

10.  Blood transfusions for treating acute chest syndrome in people with sickle cell disease.

Authors:  Roya Dolatkhah; Saeed Dastgiri
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.